Vaccination status (PCV13) of children with pneumococcal meningitis

Vaccination status (PCV13) of children with pneumococcal meningitis

Bibliographic Details
Main Authors:	Seidullayeva, Aliya, Bayesheva, Dinagul, Turdalina, Bayan, Altynbekova, Alyona, Omarova, Aliya, Khamitova, Meruert, Tashenov, Sabit, Otarbayeva, Aislu, Kozhakhmetov, Samat
Format:	Article
Language:	English
Published:	National Scientific Medical Center 2020-05-01
Series:	Ķazaķstannyṇ Klinikalyķ Medicinasy
Online Access:	http://www.clinmedkaz.org/ozet.php?makale_id=764&dil=en

Similar Items

Measles at the present stage
by: Aygerim Zhuzzhasarova, et al.
Published: (2021-12-01)

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project
by: Maria Garcia Quesada, et al.
Published: (2021-04-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021-04-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
by: Sara Tomczyk, et al.
Published: (2018-04-01)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
by: Mark van der Linden, et al.
Published: (2016-01-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019-03-01)

Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1
by: Hyunjung Kim, et al.
Published: (2022-12-01)

Whole genome sequence analysis of Neisseria meningitidis strains circulating in Kazakhstan, 2017–2018
by: Alexandr Shevtsov, et al.
Published: (2022-01-01)

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017-07-01)

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines.
by: Adamos Hadjipanayis, et al.
Published: (2016-01-01)

Invasiveness potential of pneumococcal serotypes in children after introduction of PCV13 in Blantyre, Malawi
by: Amir Kirolos, et al.
Published: (2023-01-01)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018-04-01)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
by: Jorge A. Gómez, et al.
Published: (2022-01-01)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022-01-01)

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination
by: Hans-Christian Slotved, et al.
Published: (2016-11-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children
by: Catarina Silva-Costa, et al.
Published: (2023-12-01)

Changes in Invasive pneumococcal disease caused by Streptococcus pneumoniae Serotype 1 following introduction of PCV10 and PCV13: findings from the PSERENADE Project
by: Bennett, J, et al.
Published: (2021)

Pneumococcal Meningitis
by: Kelly Di Dier, et al.
Published: (2022-12-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
by: Hannah M. Garcia Garrido, et al.
Published: (2022-05-01)

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR).
by: Rania Abu Seir, et al.
Published: (2018-01-01)

Serotype-Specific Pneumococcal Status prior to PCV 13 Administration in Children and Adolescents with Inflammatory Bowel Disease
by: Aleksandra Banaszkiewicz, et al.
Published: (2016-03-01)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024-12-01)

Changes in Invasive Pneumococcal Disease Caused by <em>Streptococcus pneumoniae</em> Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
by: Julia C. Bennett, et al.
Published: (2021-03-01)

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
by: Rotem Lapidot, et al.
Published: (2020-05-01)

Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020-12-01)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010–2019
by: Eiman Mokaddas, et al.
Published: (2021-11-01)

Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study
by: Lo, SW, et al.
Published: (2019)

Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study
by: Lourenço, J, et al.
Published: (2019)

Molecular Characterization and Antibiotic Susceptibility of Non-PCV13 Pneumococcal Serotypes among Vaccinated Children in Cape Coast, Ghana
by: Richael O. Mills, et al.
Published: (2022-10-01)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017-10-01)

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection.
by: Sophie Marbaix, et al.
Published: (2018-01-01)

Determinants of high residual post-PCV13 pneumococcal vaccine-type carriage in Blantyre, Malawi: a modelling study
by: J. Lourenço, et al.
Published: (2019-12-01)

Epidemiological situation of measles in the Republic of Kazakhstan
by: A. Zhuzzhasarova, et al.
Published: (2020-12-01)

Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.
by: John Njuma Libwea, et al.
Published: (2021-01-01)

Spread of multidrug resistance in non-PCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan
by: Mitsuyo Kawaguchiya, et al.
Published: (2023-12-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
by: Sophie Warren, et al.
Published: (2023-08-01)

Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study
by: Mathilde Bahuaud, et al.
Published: (2017-11-01)

One-step multiplex PCR assay for detecting Streptococcus pneumoniae serogroups/types covered by 13-valent pneumococcal conjugate vaccine (PCV13).
by: Fatma Filiz Coskun-Ari, et al.
Published: (2012-01-01)